Stockhub

Cantargia AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 06:0806:08, 16 August 2022 >Paris 1,063 bytes +1,063 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is und..."
Retrieved from "https://stockhub.co/research/Cantargia_AB"